These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 16715670

  • 1. Evaluation of hypoxia-specific cytotoxic bioreductive agent-sodium borocaptate-10B conjugates as 10B-carriers in boron neutron capture therapy.
    Masunaga S, Nagasawa H, Gotoh K, Sakurai Y, Uto Y, Hori H, Nagata K, Suzuki M, Maruhashi A, Kinashi Y, Ono K.
    Radiat Med; 2006 Feb; 24(2):98-107. PubMed ID: 16715670
    [Abstract] [Full Text] [Related]

  • 2. Applicability of the 2-nitroimidazole-sodium borocaptate-10B conjugate, TX-2060, as a 10B-carrier in boron neutron capture therapy.
    Masunaga S, Nagasawa H, Hiraoka M, Sakurai Y, Uto Y, Hori H, Nagata K, Suzuki M, Maruhashi A, Kinashi Y, Ono K.
    Anticancer Res; 2004 Feb; 24(5A):2975-83. PubMed ID: 15517904
    [Abstract] [Full Text] [Related]

  • 3. The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy.
    Masunaga S, Nagasawa H, Sakurai Y, Uto Y, Hori H, Nagata K, Suzuki M, Maruhashi A, Kinashi Y, Ono K.
    Int J Hyperthermia; 2006 Jun; 22(4):287-99. PubMed ID: 16754350
    [Abstract] [Full Text] [Related]

  • 4. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
    Masunaga S, Sakurai Y, Suzuki M, Nagata K, Maruhashi A, Kinash Y, Ono K.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):920-7. PubMed ID: 15465210
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Responses of total and quiescent cell populations in solid tumors to boron and gadolinium neutron capture reaction using neutrons with two different energy spectra.
    Masunaga S, Ono K, Sakurai Y, Suzuki M, Takagaki M, Kobayashi T, Kinashi Y, Akaboshi M.
    Jpn J Cancer Res; 1998 Jan 01; 89(1):81-8. PubMed ID: 9510480
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Modification of the response of a quiescent cell population within a murine solid tumour to boron neutron capture irradiation: studies with nicotinamide and hyperthermia.
    Masunaga S, Ono K, Suzuki M, Takagaki M, Sakurai Y, Kobayashi T, Akuta K, Akaboshi M, Kinashi Y, Abe M.
    Br J Radiol; 1997 Apr 01; 70(832):391-8. PubMed ID: 9166076
    [Abstract] [Full Text] [Related]

  • 10. Impact of the p53 status of the tumor cells on the effect of reactor neutron beam irradiation, with emphasis on the response of intratumor quiescent cells.
    Masunaga S, Ono K, Takahashi A, Sakurai Y, Ohnishi K, Kobayashi T, Kinashi Y, Takagaki M, Ohnishi T.
    Jpn J Cancer Res; 2002 Dec 01; 93(12):1366-77. PubMed ID: 12495477
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alteration of sensitivity of intratumor quiescent and total cells to gamma-rays following thermal neutron irradiation with or without 10B-compound.
    Masunaga S, Ono K, Suzuki M, Sakurai Y, Kobayashi T, Takagaki M, Kinashi Y, Akaboshi M.
    Int J Radiat Oncol Biol Phys; 2000 Feb 01; 46(3):653-9. PubMed ID: 10701745
    [Abstract] [Full Text] [Related]

  • 13. The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy.
    Masunaga SI, Sanada Y, Takata T, Tanaka H, Sakurai Y, Suzuki M, Kirihata M, Ono K.
    J Radiat Res; 2023 Mar 23; 64(2):399-411. PubMed ID: 36763853
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the potential of p-boronophenylalaninol as a boron carrier in boron neutron capture therapy, referring to the effect on intratumor quiescent cells.
    Masunaga SI, Ono K, Kirihata M, Takagaki M, Sakurai Y, Kinashi Y, Kobayashi T, Nagasawa H, Uto Y, Hori H.
    Jpn J Cancer Res; 2001 Sep 23; 92(9):996-1007. PubMed ID: 11572769
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Usefulness of combination with both continuous administration of hypoxic cytotoxin and mild temperature hyperthermia in boron neutron capture therapy in terms of local tumor response and lung metastatic potential.
    Masunaga SI, Sakurai Y, Tanaka H, Takata T, Suzuki M, Sanada Y, Tano K, Maruhashi A, Ono K.
    Int J Radiat Biol; 2019 Dec 23; 95(12):1708-1717. PubMed ID: 31545117
    [Abstract] [Full Text] [Related]

  • 17. Repair of potentially lethal damage by total and quiescent cells in solid tumors following a neutron capture reaction.
    Masunaga S, Ono K, Suzuki M, Sakurai Y, Takagaki M, Kobayashi T, Kinashi Y, Akaboshi M.
    J Cancer Res Clin Oncol; 1999 Nov 23; 125(11):609-14. PubMed ID: 10541967
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S, Uto Y, Nagasawa H, Hori H, Nagata K, Suzuki M, Kinashi Y, Ono K.
    Anticancer Res; 2006 Nov 23; 26(2A):1261-70. PubMed ID: 16619533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.